Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox

Bibliographic Details
Main Authors:	Shogo Amano, Seiji Kaino, Shuhei Shinoda, Hirofumi Harima, Toshihiko Matsumoto, Koichi Fujisawa, Taro Takami, Naoki Yamamoto, Takahiro Yamasaki, Isao Sakaida
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	BMC Cancer
Online Access:	https://doi.org/10.1186/s12885-023-11091-y

Similar Items

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2020-07-01)

Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2023-12-01)

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells
by: Koichi Fujisawa, et al.
Published: (2022-05-01)

Metabolic Alterations in Spheroid-Cultured Hepatic Stellate Cells
by: Koichi Fujisawa, et al.
Published: (2020-05-01)

Metabolic Analysis of DFO-Resistant Huh7 Cells and Identification of Targets for Combination Therapy
by: Koichi Fujisawa, et al.
Published: (2023-10-01)

Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells
by: Koichi Fujisawa, et al.
Published: (2018-04-01)

Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver
by: Koichi Fujisawa, et al.
Published: (2017-06-01)

Seasonal variations in photoperiod affect hepatic metabolism of medaka (Oryzias latipes)
by: Koichi Fujisawa, et al.
Published: (2021-04-01)

Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma
by: Toshiyuki Uekitani, et al.
Published: (2016-01-01)

Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging.
by: Koichi Fujisawa, et al.
Published: (2015-01-01)

Correction: Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging.
by: Koichi Fujisawa, et al.
Published: (2015-01-01)

Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose
by: Koichi Fujisawa, et al.
Published: (2021-09-01)

Evaluation of the Effects of Microgravity on Activated Primary Human Hepatic Stellate Cells
by: Koichi Fujisawa, et al.
Published: (2022-07-01)

Assessment of high-fat-diet-induced fatty liver in medaka
by: Koichi Fujisawa, et al.
Published: (2018-11-01)

Deferasirox, an oral chelator in the treatment of iron overload
by: I. Portioli
Published: (2013-05-01)

Pharmacogenetic study of deferasirox, an iron chelating agent.
by: Ji Won Lee, et al.
Published: (2013-01-01)

A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
by: Issei Saeki, et al.
Published: (2015-01-01)

Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model.
by: Tatsuro Nishimura, et al.
Published: (2019-01-01)

Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
by: Issei Saeki, et al.
Published: (2019-01-01)

Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
by: Murtadha Al-Khabori, et al.
Published: (2013-03-01)

Adenylate Kinase Isozyme 3 Regulates Mitochondrial Energy Metabolism and Knockout Alters HeLa Cell Metabolism
by: Koichi Fujisawa, et al.
Published: (2022-04-01)

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjiC domain-containing histone demethylases
by: Roatsch, M, et al.
Published: (2019)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
by: PLOS ONE Staff
Published: (2019-01-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
by: Yurika Kotoh, et al.
Published: (2020-08-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
by: Mohamed Abdel Malik Hassan, et al.
Published: (2016-05-01)

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis
by: Fucile C, et al.
Published: (2018-09-01)

Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
by: Takahiro Yamasaki, et al.
Published: (2021-02-01)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
by: Toshihiko Matsumoto, et al.
Published: (2023-07-01)

Granulocyte Colony-Stimulating Factor and Interleukin-1β are Important Cytokines in Repair of the Cirrhotic Liver after Bone Marrow Cell Infusion: Comparison of Humans and Model Mice
by: Yuko Mizunaga, et al.
Published: (2012-11-01)

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Cappellini, M.D., et al.
Published: (2010)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010)

P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY
by: Mathilde Veneziano, et al.
Published: (2023-08-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
by: A. Piga, et al.
Published: (2022-06-01)

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells
by: Chiara Calabrese, et al.
Published: (2020-10-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Duodenal perforation caused by deferasirox “case report”
by: Mohammmed Al Blooshi, et al.
Published: (2023-07-01)

Deferasirox – a rarer cause of Fanconi syndrome
by: Iman Khan, et al.
Published: (2019-07-01)